Jerome Guitton
Overview
Explore the profile of Jerome Guitton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pagnot L, Granger I, Guitton J, Favier B, Ceraulo A, Faure-Conter C, et al.
Cancer Chemother Pharmacol
. 2025 Feb;
95(1):35.
PMID: 39998657
Purpose: Trametinib, a MEK1/2 inhibitor, has emerged as a promising treatment for pediatric patients with low-grade gliomas (LGG). However, trametinib exhibits significant inter-individual pharmacokinetic (PK) variability, and studies in adults...
2.
Barthelemy D, Vigneron A, Rousset X, Guitton J, Grolleau E, Raffin M, et al.
FEBS Open Bio
. 2025 Jan;
PMID: 39887892
Non-small cell lung cancer (NSCLC) affects 10-50% of patients with epidermal growth factor receptor (EGFR) mutations. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that radically changes the outcome...
3.
Vignaud E, Goutelle S, Genestet C, Guitton J, Cohen S, Bourg C, et al.
Ann Clin Microbiol Antimicrob
. 2025 Jan;
24(1):10.
PMID: 39885508
Background: Mycobacterium abscessus (MABS) causes difficult-to-treat pulmonary and extra-pulmonary infections. A combination therapy comprising amikacin, cefoxitin, and a macrolide agent is recommended, but its antimicrobial activity and clinical efficacy is...
4.
Favier B, Simonin C, Tokatian S, Guitton J, Darnis S, Basset M, et al.
J Oncol Pharm Pract
. 2024 Dec;
31(2):305-314.
PMID: 39703089
ObjectiveDespite significant advances in cancer treatment with targeted therapies and immunotherapies, cytotoxic chemotherapies are still extensively used. Potential cytotoxic contamination in preparing and administrating cytotoxics is still a major source...
5.
Matusik E, Vassal O, Conrad A, Ferry T, Millet A, Dupont D, et al.
Antimicrob Agents Chemother
. 2024 Sep;
68(11):e0099124.
PMID: 39324800
Large pharmacokinetic (PK) variability of fluconazole has been reported in critically ill patients, but the implications for fluconazole dosing remain unclear. The objectives of this study were to evaluate the...
6.
Mashal M, Guitton J, Sallet P, Bourguignon L, Machon C
Drug Test Anal
. 2024 Aug;
PMID: 39148281
Monitoring of drug use in athletes is of interest both for health and competition-related issues. Considering the advantages of Dried Blood Sampling (low invasiveness, easy sampling, long term storage), we...
7.
Thomas F, Launay M, Raymond L, Guitton J, Loriot M, Chatelut E, et al.
Clin Chem Lab Med
. 2024 Aug;
62(12):e257-e259.
PMID: 39141832
No abstract available.
8.
Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, et al.
Clin Pharmacokinet
. 2024 Jul;
63(7):1025-1036.
PMID: 38963459
Background And Objective: Trough abiraterone concentration (ABI C) of 8.4 ng/mL has been identified as an appropriate efficacy threshold in patients treated for metastatic castration-resistant prostate cancer (mCRPC). The aim...
9.
Launay M, Raymond L, Guitton J, Loriot M, Chatelut E, Haufroid V, et al.
Clin Chem Lab Med
. 2024 Jun;
62(12):2415-2424.
PMID: 38896022
Objectives: Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of severe fluoropyrimidine-related toxicities. The best strategy for identifying DPD-deficient patients is still not defined. The EMA recommends targeted genotyping or...
10.
Al Assi A, Posty S, Lamarche F, Chebel A, Guitton J, Cottet-Rousselle C, et al.
Cell Death Dis
. 2024 May;
15(5):311.
PMID: 38697987
Cancer cells are highly dependent on bioenergetic processes to support their growth and survival. Disruption of metabolic pathways, particularly by targeting the mitochondrial electron transport chain complexes (ETC-I to V)...